|
1.
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Berasain C, Castillo J, Perugorria MJ,
Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer:
new molecular links. Ann NY Acad Sci. 1155:206–221. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Stauffer JK, Scarzello AJ, Jiang Q and
Wiltrout RH: Chronic inflammation, immune escape and oncogenesis in
the liver: a unique neighborhood for novel intersections.
Hepatology. 56:1567–1574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Hu KQ: Cyclooxygenase 2 (COX2)-prostanoid
pathway and liver diseases. Prostaglandins Leukot Essent Fatty
Acids. 69:329–337. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Wu T: Cyclooxygenase-2 in hepatocellular
carcinoma. Cancer Treat Rev. 32:28–44. 2006. View Article : Google Scholar
|
|
6.
|
Ma J, Chen M, Xia SK, et al: Prostaglandin
E2 promotes liver cancer cell growth by the upregulation
of FUSE-binding protein 1 expression. Int J Oncol. 42:1093–1104.
2013.
|
|
7.
|
Bai XM, Jiang H, Ding JX, et al:
Prostaglandin E2 upregulates survivin expression via the
EP1 receptor in hepatocellular carcinoma cells. Life Sci.
86:214–223. 2009.
|
|
8.
|
Gomes RN and Colquhoun A: E series
prostaglandins alter the proliferative, apoptotic and migratory
properties of T98G human glioma cells in vitro. Lipids Health Dis.
11:1712012. View Article : Google Scholar
|
|
9.
|
Sun B, Rong R, Jiang H, et al:
Prostaglandin E2 receptor EP1 phosphorylate CREB and
mediates MMP2 expression in human cholangiocarcinoma cells. Mol
Cell Biochem. 378:195–203. 2013.
|
|
10.
|
Xin X, Majumder M, Girish GV, Mohindra V,
Maruyama T and Lala PK: Targeting COX-2 and EP4 to control tumor
growth, angiogenesis, lymphangiogenesis and metastasis to the lungs
and lymph nodes in a breast cancer model. Lab Invest. 92:1115–1128.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Valastyan S and Weinberg RA: Tumor
metastasis: molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lasham A, Print CG, Woolley AG, Dunn SE
and Braithwaite AW: YB-1: oncoprotein, prognostic marker and
therapeutic target? Biochem J. 449:11–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bargou RC, Jurchott K, Wagener C, et al:
Nuclear localization and increased levels of transcription factor
YB-1 in primary human breast cancers are associated with intrinsic
MDR1 gene expression. Nat Med. 3:447–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Shibahara K, Sugio K, Osaki T, et al:
Nuclear expression of the Y-box binding protein, YB-1, as a novel
marker of disease progression in non-small cell lung cancer. Clin
Cancer Res. 7:3151–3155. 2001.PubMed/NCBI
|
|
15.
|
Gimenez-Bonafe P, Fedoruk MN, Whitmore TG,
et al: YB-1 is upregulated during prostate cancer tumor progression
and increases P-glycoprotein activity. Prostate. 59:337–349. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Lasham A, Samuel W, Cao H, et al: YB-1,
the E2F pathway and regulation of tumor cell growth. J Natl Cancer
Inst. 104:133–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Dahl E, En-Nia A, Wiesmann F, et al:
Nuclear detection of Y-box protein-1 (YB-1) closely associates with
progesterone receptor negativity and is a strong adverse survival
factor in human breast cancer. BMC Cancer. 9:4102009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Habibi G, Leung S, Law JH, et al:
Redefining prognostic factors for breast cancer: YB-1 is a stronger
predictor of relapse and disease-specific survival than estrogen
receptor or HER-2 across all tumor subtypes. Breast Cancer Res.
10:R862008. View Article : Google Scholar
|
|
19.
|
Huang J, Tan PH, Li KB, Matsumoto K,
Tsujimoto M and Bay BH: Y-box binding protein, YB-1, as a marker of
tumor aggressiveness and response to adjuvant chemotherapy in
breast cancer. Int J Oncol. 26:607–613. 2005.PubMed/NCBI
|
|
20.
|
Evdokimova V, Tognon C, Ng T, et al:
Translational activation of snail1 and other developmentally
regulated transcription factors by YB-1 promotes an
epithelial-mesenchymal transition. Cancer Cell. 15:402–415. 2009.
View Article : Google Scholar
|
|
21.
|
Bai X, Wang J, Zhang L, et al:
Prostaglandin E2 receptor EP1-mediated phosphorylation
of focal adhesion kinase enhances cell adhesion and migration in
hepatocellular carcinoma cells. Int J Oncol. 42:1833–1841.
2013.
|
|
22.
|
Bai XM, Zhang W, Liu NB, et al: Focal
adhesion kinase: important to prostaglandin E2-mediated
adhesion, migration and invasion in hepatocellular carcinoma cells.
Oncol Rep. 21:129–136. 2009.PubMed/NCBI
|
|
23.
|
Ho MY, Liang SM, Hung SW and Liang CM:
MIG-7 controls COX-2/PGE2-mediated lung cancer
metastasis. Cancer Res. 73:439–449. 2012.PubMed/NCBI
|
|
24.
|
Pai R, Nakamura T, Moon WS and Tarnawski
AS: Prostaglandins promote colon cancer cell invasion; signaling by
cross-talk between two distinct growth factor receptors. FASEB J.
17:1640–1647. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Dohadwala M, Batra RK, Luo J, et al:
Autocrine/paracrine prostaglandin E2 production by
non-small cell lung cancer cells regulates matrix
metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent
invasion. J Biol Chem. 277:50828–50833. 2002.PubMed/NCBI
|
|
26.
|
Wu Y, Yamada S, Izumi H, et al: Strong
YB-1 expression is associated with liver metastasis progression and
predicts shorter disease-free survival in advanced gastric cancer.
J Surg Oncol. 105:724–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Lovett DH, Cheng S, Cape L, Pollock AS and
Mertens PR: YB-1 alters MT1-MMP trafficking and stimulates MCF-7
breast tumor invasion and metastasis. Biochem Biophys Res Commun.
398:482–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Han C, Michalopoulos GK and Wu T:
Prostaglandin E2 receptor EP1 transactivates EGFR/MET
receptor tyrosine kinases and enhances invasiveness in human
hepatocellular carcinoma cells. J Cell Physiol. 207:261–270.
2006.
|
|
29.
|
Han C and Wu T: Cyclooxygenase-2-derived
prostaglandin E2 promotes human cholangiocarcinoma cell
growth and invasion through EP1 receptor-mediated activation of the
epidermal growth factor receptor and Akt. J Biol Chem.
280:24053–24063. 2005.PubMed/NCBI
|
|
30.
|
Caramel J, Papadogeorgakis E, Hill L, et
al: A switch in the expression of embryonic EMT-inducers drives the
development of malignant melanoma. Cancer Cell. 24:466–480. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Caslavsky J, Klimova Z and Vomastek T: ERK
and RSK regulate distinct steps of a cellular program that induces
transition from multicellular epithelium to single cell phenotype.
Cell Signal. 25:2743–2751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Weiss MB, Abel EV, Mayberry MM, Basile KJ,
Berger AC and Aplin AE: TWIST1 is an ERK1/2 effector that promotes
invasion and regulates MMP-1 expression in human melanoma cells.
Cancer Res. 72:6382–6392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Liu JF, Fong YC, Chang CS, et al:
Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell
migration via EP1 dependent signaling pathway in human
chondrosarcoma cells. Mol Cancer. 9:432010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003.
|
|
36.
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelialmesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Matsumoto K and Wolffe AP: Gene regulation
by Y-box proteins: coupling control of transcription and
translation. Trends Cell Biol. 8:318–323. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Kuwano M, Uchiumi T, Hayakawa H, et al:
The basic and clinical implications of ABC transporters,
Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in
human malignancies. Cancer Sci. 94:9–14. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Evdokimova V, Ovchinnikov LP and Sorensen
PH: Y-box binding protein 1: providing a new angle on translational
regulation. Cell Cycle. 5:1143–1147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Guo TT, Yu YN, Cheong Yip GW, Matsumoto K
and Bay BH: Silencing the YB-1 gene inhibits cell migration in
gastric cancer in vitro. Anat Rec. 296:891–898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Delcourt N, Bockaert J and Marin P:
GPCR-jacking: from a new route in RTK signalling to a new concept
in GPCR activation. Trends Pharmacol Sci. 28:602–607. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Santamaria PG and Nebreda AR:
Deconstructing ERK signaling in tumorigenesis. Mol Cell. 38:3–5.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Ellenrieder V, Hendler SF, Boeck W, et al:
Transforming growth factor beta1 treatment leads to an
epithelial-mesenchymal trans-differentiation of pancreatic cancer
cells requiring extracellular signal-regulated kinase 2 activation.
Cancer Res. 61:4222–4228. 2001.
|
|
45.
|
Fujiwara-Okada Y, Matsumoto Y, Fukushi J,
et al: Y-box binding protein-1 regulates cell proliferation and is
associated with clinical outcomes of osteosarcoma. Br J Cancer.
108:836–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
